Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 12/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.33 |
| ▸ | FGF1 | P05230 | 2/20 | 0.32 |
| ▸ | FGF2 | P09038 | 2/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191756 | 0.93 | TLR4 (0.46) | TLR4MAPK1CNR1CNR2LY96 | |
| SCHEMBL12600785 | 0.86 | TLR4 (0.38) | TLR4MAPK1LY96 | |
| SCHEMBL12762964 | 0.86 | TLR4 (0.38) | TLR4MAPK1LY96 | |
| SCHEMBL4201760 | 0.83 | TLR4 (0.36) | TLR4MAPK1CNR1CNR2 | |
| SCHEMBL4201764 | 0.83 | TLR4 (0.36) | TLR4MAPK1CNR1CNR2 | |
| SCHEMBL13296761 | 0.81 | TLR4 (0.39) | TLR4MAPK1LY96FGF1FGF2 | |
| SCHEMBL12371590 | 0.81 | TLR4 (0.39) | TLR4MAPK1LY96FGF1FGF2 | |
| SCHEMBL12600842 | 0.80 | TLR4 (0.45) | TLR4MAPK1LY96 | |
| SCHEMBL12600975 | 0.80 | TLR4 (0.45) | TLR4MAPK1LY96 | |
| SCHEMBL4204256 | 0.80 | MAPK1 (0.52) | TLR4MAPK1LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | TLR4 294/4885MAPK1 1294/4885CNR1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.